Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-Mutated Advanced Solid Tumours

NCT01143753 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01143753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01143753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multiple Ascending Dose (MAD) Study of the Selective BRAF Inhibitor RO5212054 (PLX3603) to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With BRAF V600-Mutated Advanced Solid Tumours
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1
Overall status
Completed
Start date
July 27, 2010
Completion date
May 2, 2017
Enrollment
45 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms